Summit Therapeutics Inc. SMMT
15.80 USD +1.00 (+6.76%)
At closeNov 3, 2026, 4:00 PM EST
15.98 +0.18 +1.14%
After hours · Nov 3, 4:00 PM ET
14.86 Day range 16.42
12.07 52-week range 29.23
- YTD
- -9.66%
- 1 year
- -13.28%
Analyst view
Consensus: buy
Buy
Price target (mean) 30.29 +91.7% upside
Now 15.80
- Target (low)
- 11.93
- Target (mean)
- 30.29
- Target (high)
- 43.86
Ratings (0m) 17 11 buy · 6 hold · 0 sell
- Strong buy1
- Buy10
- Hold6
- Sell0
- Strong sell0
Recommendation trend
- This month 17
- 1 month ago 17
- 2 months ago 17
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.20808 | -0.315 – -0.106 | -0.23145 | +10.1% | 53.79K | 0.0% | 12 |
| Next quarter | -0.25818 | -0.514 – -0.043 | -0.21477 | -20.2% | 2.99M | 0.0% | 11 |
| Current year | -0.83918 | -1.22 – -0.496 | -1.07 | +21.3% | 2.94M | 0.0% | 11 |
| Next year | -0.8769 | -1.22 – -0.442 | -0.83918 | -4.5% | 41.94M | +1328.4% | 10 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 1, 2026 | Barclays | Maintained | Equal-Weight | Equal-Weight |
| Sep 29, 2026 | Citigroup | Maintained | Buy | Buy |
| Sep 23, 2026 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Sep 9, 2026 | Jefferies | Upgrade | Hold | Buy |
| Aug 26, 2026 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Aug 25, 2026 | Bernstein | Upgrade | Underperform | Market Perform |
| Aug 18, 2026 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| Aug 12, 2026 | Leerink Partners | Upgrade | Underperform | Market Perform |
| Jul 24, 2026 | Stifel | Maintained | Buy | Buy |
| Jul 24, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jul 23, 2026 | HC Wainwright & Co. | Reiterated | Neutral | Neutral |
| May 22, 2026 | Bernstein | Initiated | — | Underperform |
| May 22, 2026 | HC Wainwright & Co. | Downgrade | Buy | Neutral |
| May 4, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| May 1, 2026 | Piper Sandler | Maintained | Neutral | Neutral |
| Apr 8, 2026 | Stifel | Initiated | Buy | Buy |
| Mar 16, 2026 | Jefferies | Downgrade | Buy | Hold |
| Feb 24, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Feb 2, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jan 30, 2026 | Citizens | Reiterated | Market Outperform | Market Outperform |
| Dec 17, 2025 | Barclays | Upgrade | Underweight | Equal-Weight |
| Nov 18, 2025 | Wolfe Research | Initiated | — | Peer Perform |
| Oct 22, 2025 | Guggenheim | Reiterated | Buy | Buy |
| Oct 21, 2025 | Barclays | Maintained | Underweight | Underweight |
| Oct 21, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Oct 20, 2025 | Citigroup | Maintained | Buy | Buy |
| Oct 20, 2025 | JMP Securities | Reiterated | Market Outperform | Market Outperform |
| Sep 17, 2025 | Barclays | Initiated | — | Underweight |
| Sep 16, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 8, 2025 | Cantor Fitzgerald | Reiterated | Overweight | Overweight |